Table 1.
Characteristics of patients with and without uveitis
| Characteristics | Uveitis (N = 14) | No uveitis (N = 13) | p-valuea |
|---|---|---|---|
| Mean age in years (SD) | 14.1 (3.2) | 13.6 (3.2) | |
| Female | 9 (64.3%) | 8 (61.5%) | |
| Arthritis | 10 (71%) | 13 (100%) | |
| ANA (+) | 10 (71.4%) | 5 (38.5%) | |
| Arthritis characteristics | |||
| Median duration in years (range) | 5 (0-15) | 3 (1-8) | |
| AM stiffness | 1 (7.1%) | 7 (53.8%) | |
| Painful joints in last month | 3 (21.4%) | 5 (38.5%) | |
| Painful joints ever | 12 (85.7%) | 13 (100%) | |
| Swollen joints in last month | 2 (14.3%) | 3 (23.1%) | |
| Swollen joints ever | 8 (57.1%) | 10 (76.9%) | |
| Median physician's global assessment, 0-10 (range) | 5 (1-7) | 3 (2-7) | |
| Median ESR at diagnosis (range) | 8.5 (1-63) | 17 (1-87) | |
| Uveitis characteristics | |||
| Median duration uveitis in years (range) | 5 (1-12) | ||
| Eye pain | 5 (36%) | 1 (8%) | 0.165 |
| Eye redness | 7 (50%) | 1 (8%) | 0.033 |
| Photophobia | 8 (57%) | 1 (8%) | 0.013 |
| Cataracts | 4 (29%) | 0 | 0.098 |
| Glaucoma | 3 (21%) | 0 | 0.222 |
| Prior and current medications | |||
| Prednisone | 7 (50%) | 3 (23%) | |
| Methotrexate | 8 (57%) | 8 (62%) | |
| Infliximab | 5 (36%) | 1 (8%) | |
| Etanercept | 4 (29%) | 6 (46%) | |
| Adalimumab | 8 (57%) | 3 (23%) | |
| Daclizumab | 2 (14%) | 0 |
a
Bonferroni's correction used for multiple comparisons
*
p < 0.010.